MA-OPTIKOS
12.9.2022 20:32:37 CEST | Business Wire | Press release
Optikos Corporation introduced three new products to its OpTest® and Meridian® lens and camera metrology product lines, developed to address the specific requirements for testing and image capture conditions in the field of automotive imaging.
Optikos has a long history of pioneering the development and commercialization of test equipment for the evaluation of lenses and cameras, including the OpTest® and LensCheck™ product families, widely regarded as the gold standard for assessing the image quality of lens assemblies; and the Meridian product line, for measuring the performance of an assembled camera. The Company is recognized not only for its comprehensive range of standard products, but also its readiness to customize hardware and software to suit a customer’s particular requirements such as those demanded in automotive imaging applications.
With two of its newest products, Optikos has extended its expertise in measuring the effects of stray light in lenses to camera assemblies—with the Meridian camera testing line now including products that serve as sources for measuring Veiling Glare Index (VGI) and Glare Spread Function (GSF).
VGI measurements are useful as a measure of diffuse irradiance on the image plane, and require a uniformly illuminated background field populated with one or more dark objects. The new Meridian VGI source is a customizable hemispherical integrating sphere into which light traps of various sizes may be fitted; and enables the customer to specify the sizes and locations of the light traps according to the characteristics of the camera assemblies to be tested. The system is illuminated using white LEDs, the intensity of which may be remotely controlled.
Glare Spread Function testing evaluates the severity of ghost reflections or other prominent stray light artifacts that form concentrated irradiation patterns. The new Meridian Sol-55 projector addresses this need with a modular design, and features interchangeable object aperture drawers for controlling the angular extent of the projected target, and an aperture wheel that controls the numerical aperture of the illumination through the object aperture. “The unique design avoids overfilling the lens under test and creating a secondary source of stray light from adjacent scattering surfaces; while illumination is provided by a high intensity white LED which can be remotely controlled for high dynamic range measurements,” said David Imrie, Optikos Chief Technology Officer.
Meridian Sol-55 projectors are designed to be flexibly mounted at pre-determined field points with respect to the device-under-test in rigid assemblies that form a Meridian Sunfield system. They are distinguished from Meridian Starfield assemblies of Static Target Projectors (STPs) used in image quality (MTF) testing of cameras.
In addition to stray light, temperature extremes pose a significant challenge for image sensor performance in automotive cameras. Optikos has been testing lenses across a range of temperatures in its IQ Lab™ Optical Testing Service since 2017, and first productized this process for testing lenses up to 150mm with its Thermal Module TM-1150 system.
The new TC-1065 is a thermal chamber used for lens testing that extends the maximum size of lenses that may be tested over a range of temperatures on a LensCheck system, complementing the smaller TC-1050 and TC-1010 products also available in the product line. In order to optimize the thermal performance, the thermal chamber is generally sized to match the dimensions of the lenses with which it will be used.
Optikos will be exhibiting at AutoSens Brussels 2022 on October 12-14th. To learn more about Optikos solutions for automotive imaging, see contact details below.
About Optikos
The Optical Engineering Experts®—Optikos provides leading-edge applications of optical technology to organizations worldwide. For customers who require optical testing and image quality assessment of lens and camera systems, we offer an advanced line of standard and custom metrology products as well as in-house IQ Lab™ Optical Testing Services. We offer product development services that include a broad range of engineering, contract manufacturing, and assembly capabilities. Our broad skill set, including optics, mechanics, electronics, automation, and software systems, enables us to quickly understand our customers' unique technical requirements and provide a flexible and scalable resource. Applications range from medical devices and diagnostics to aerial imaging, defense, automotive cameras, and well beyond.
For more information, visit optikos.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220912005764/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bial Announces Completion of Phase 2b ACTIVATE Study with BIA 28-6156 in GBA1-Associated Parkinson’s26.5.2026 08:00:00 CEST | Press release
Study Topline results will be released around the end of Q2 2026 BIA 28-6156 is being developed as a potential first-in-class disease-modifying therapy in GBA-PD Bial was present at the GBA1 conference and is currently attending the World Parkinson Congress Bial, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, today announced the completion of the treatment period in its Phase 2b ACTIVATE study of BIA 28-6156 (pariceract) in patients with Parkinson’s disease (PD) who have a pathogenic mutation in the glucocerebrosidase 1 (GBA1) gene (GBA-PD). Upon completion of the 78-week double-blind treatment period and all scheduled safety follow-ups, data cleaning and analysis are currently ongoing. Topline results will be released around the end of Q2. A status report on the ACTIVATE study was presented in an oral presentation at the 3rd International GBA1 Meeting 2026. The team is currently attending the 7th World Parkinson Congress, taking place in Pho
Oticon Medical Introduces Ponto™ Instant, Expanding Non-Surgical Choice with Instant HearBand and Instant SoundConnector26.5.2026 07:00:00 CEST | Press release
Oticon Medical today announces its new non-surgical portfolio, Ponto Instant, designed to broaden access to bone conduction hearing and offer more choice for users and hearing care professionals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260525771593/en/ Left: Instant HearBand, a discreet behind-the-head wearable solution that offers an alternative to Softband 5. Right: Instant SoundConnector, a small accessory fitted to a cap or other headwear, providing another non-surgical way to wear a Ponto sound processor. The Ponto Instant portfolio includes Softband 5, Oticon Medical’s established and trusted non-surgical solution, and now expands with the launch of Instant HearBand and Instant SoundConnector, further strengthening its wearable offering for children and adults who prefer a non-surgical solution. Instant HearBand: a discreet new wearable alternative As part of the new portfolio, Instant HearBand is introduced as
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
